Table 1 Associations of Eph-A1 and -A4 expression with clinicopathological characteristics in 88 NSCLC patients
Clinicopathological characteristics | Eph-A1 expression | Eph-A4 expression | ||||
|---|---|---|---|---|---|---|
Negative/weak | Moderate/high | p-value | Negative/weak | Moderate/high | p-value | |
N = 88 | 73 (83.0) | 15 (17.0) | 64 (72.7) | 24 (27.3) | ||
Age (mean ± SD;ys) | 0.511 | 0.486 | ||||
≤ 64.47 ± 9.18 yrs | 36 (40.9) | 6 (6.8) | 32 (36.4) | 10 (11.4) | ||
> 64.47 ± 9.18 yrs | 37 (42.0) | 9 (10.2) | 32 (36.4) | 14 (15.9) | ||
Gender | 0.841 | 0.693 | ||||
Female | 13 (14.8) | 3 (3.4) | 11 (12.5) | 5 (5.7) | ||
Male | 60 (68.2) | 12 (13.6) | 53 (60.2) | 19 (21.6) | ||
Histopathological type | 0.748 | 0.258 | ||||
Adenocarcimoma | 47 (53.4) | 9 (10.2) | 43 (48.9) | 7 (14.8) | ||
Squamous | 26 (29.5) | 6 (6.8) | 21 (23.9) | 11 (12.5) | ||
Histopathological grade | 0.569 | 0.963 | ||||
I + II | 48 (54.5) | 11 (12.5) | 43 (48.9) | 16 (18.2) | ||
III | 25 (28.4) | 4 (4.5) | 21 (23.9) | 8 (9.1) | ||
Smoking status | 0.792 | 0.837 | ||||
Yes | 65 (73.9) | 13 (14.8) | 57 (64.8) | 21 (23.9) | ||
No | 8 (9.1) | 2 (2.3) | 7 (14.8) | 3 (3.4) | ||
Alcohol consumption | 0.398 | 0.503 | ||||
Systematic | 40 (45.5) | 10 (11.4) | 36 (40.9) | 14 (15.9) | ||
No systematic | 33 (37.5) | 5 (5.7) | 28 (31.8) | 10 (11.4) | ||
Performance status | 0.453 | 0.469 | ||||
0-1 | 63 (71.6) | 14 (15.9) | 55 (62.5) | 22 (25.0) | ||
2 | 10 (11.4) | 1 (1.1) | 9 (10.2) | 2 (2.3) | ||
Inflammation | 0.869 | 0.026 | ||||
Yes | 16 (18.2) | 3 (3.4) | 10 (11.4) | 9 (10.2) | ||
No | 57 (64.8) | 12 (13.6) | 54 (61.4) | 15 (17.0) | ||
Lymphovascular invasion | 0.788 | 0.273 | ||||
Yes | 22 (25.0) | 4 (4.5) | 21 (23.9) | 5 (5.7) | ||
No | 51 (58.0) | 11 (12.5) | 43 (48.9) | 19 (21.6) | ||
Necrosis | 0.785 | 0.253 | ||||
Yes | 41 (46.6) | 9 (10.2) | 34 (38.6) | 16 (18.2) | ||
No | 32 (36.4) | 6 (6.8) | 30 (34.1) | 8 (9.1) | ||
Fibrosis | 0.593 | 0.821 | ||||
Yes | 14 (15.9) | 2 (2.3) | 12 (13.6) | 4 (4.5) | ||
No | 59 (67.0) | 13 (14.8) | 52 (59.1) | 20 (22.7) | ||
Tumor size | 0.941 | 0.700 | ||||
T1 | 14 (15.9) | 3 (3.4) | 13 (14.8) | 4 (4.5) | ||
T2-4 | 59 (67.0) | 12 (13.6) | 51 (58.0) | 20 (22.7) | ||
Lymph node metastases | 0.091 | 0.062 | ||||
N0-1 | 47 (53.4) | 13 (14.8) | 40 (45.5) | 20 (22.7) | ||
N1-2 | 26 (29.5) | 2 (2.3) | 24 (27.3) | 4 (4.5) | ||
Distant metastases | 0.250 | 0.120 | ||||
M0 | 67 (76.1) | 15 (17.0) | 58 (65.9) | 24 (27.3) | ||
M1 | 6 (6.8) | 0 (0.0) | 6 (6.8) | 0 (0.0) | ||
Histopathological stage | 0.185 | 0.047 | ||||
I + II | 40 (45.5) | 11 (12.5) | 33 (37.5) | 18 (20.5) | ||
III + IV | 33 (37.5) | 4 (4.5) | 31 (35.2) | 6 (6.8) | ||
Ki-67 protein statement | 0.047 | 0.104 | ||||
< mean value | 35 (39.8) | 3 (3.4) | 31 (35.2) | 7 (8.0) | ||
≥ mean value | 38 (43.2) | 12 (13.6) | 33 (37.5) | 17 (19.3) | ||